NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDInfliximab Remsima® Gastro-intestinal system, Cytokine inhibitors, 01.05.03
REDInfliximab Remsima® Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
REDInfliximab Remsima® Skin, Drugs affecting the immune response, 13.05.03
REDInfliximab solution for injection Pre-filled pen Remsima® Gastro-intestinal system, Cytokine inhibitors, 01.05.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Infliximab Infliximab Gastro-Intestinal System, Chronic Bowel Disorders, Inflammatory Bowel Disease, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Infliximab Infliximab Musculoskeletal System, Arthritis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Infliximab Infliximab Skin, Inflammatory Skin Conditions, Eczema And Psoriasis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
JPC: Infliximab for the management of diarrhoea or colitis associated with Immune Checkpoint Inhibitor (ICPI) therapy
JPC: Infliximab for the management of diarrhoea or colitis associated with Immune Checkpoint Inhibitor (ICPI) therapy (December 2019)
NICE TA 715 Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE TA134: Infliximab for psoriasis
NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199)
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis